Gefitinib Lung Cancer Trial Terminated Early

A randomized phase III trial of adjuvant gefitinib in patients with completely resected non–small-cell lung cancer (NSCLC) was closed early, but available results suggest that the drug is unlikely to benefit this group of patients.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news